Langedijk, Annefleur C.
Bont, Louis J. http://orcid.org/0000-0003-3099-4475
Article History
Accepted: 17 May 2023
First Online: 12 July 2023
Competing interests
: L.J.B. has regular interaction with pharmaceutical and other industrial partners. He has not received personal fees or other personal benefits. University Medical Centre Utrecht (UMCU) has received major funding (>€100,000 per industrial partner) for investigator-initiated studies from AbbVie, MedImmune, AstraZeneca, Sanofi, Janssen, Pfizer, MSD and MeMed Diagnostics. UMCU has received major funding for the RSV GOLD study from the Bill and Melinda Gates Foundation. UMCU has received major funding as part of the public–private partnership Innovative Medicines Initiative (IMI)-funded RESCEU and PROMISE projects with partners GSK, Novavax, Janssen, AstraZeneca, Pfizer and Sanofi. UMCU has received major funding from Julius Clinical for participating in clinical studies sponsored by MedImmune and Pfizer. UMCU received minor funding (€1,000–25,000 per industrial partner) for consultation and invited lectures by AbbVie, MedImmune, Ablynx, Bavaria Nordic, MabXience, GSK, Novavax, Pfizer, Moderna, AstraZeneca, MSD, Sanofi and Janssen. L.J.B. is the founding chairman of the ReSViNET Foundation. Since April 1, 2021, L.J.B. has been given a new position as medical scientific division manager of the Children’s Division of the Wilhelmina Children’s Hospital in Utrecht. A.C.L. has no conflict of interest to disclose.